Cipla Stock Screener | Share Price & Fundamental Analysis
CIPLA
Pharmaceuticals
Share Price NSE
₹1341.10
▲
12.20 (0.92%)
Share Price BSE
₹1341.45
▲
12.40 (0.93%)
Track Cipla share price live with TickJournal's free stock screener.
Analyze Cipla share price history trends and compare 52-week high low
levels.
Calculate CIPLA stock fair value using fundamental analysis and view live share price charts.
Determine Cipla share intrinsic value and compare it with current CIPLA share price.
Record your Cipla trades in TickJournal's free trading journal and track your portfolio performance.
Cipla Market Cap
₹107,554.81 Cr.
CIPLA P/E Ratio (TTM)
23.69
Cipla P/B Ratio
3.26
EPS (TTM)
₹65.29
Dividend Yield
1.20%
Debt to Equity
0.02
CIPLA 52 Week High
₹1645.10
Cipla 52 Week Low
₹1311.60
Operating Margin
12.00%
Profit Margin
9.40%
CIPLA Revenue (TTM)
₹7,169.00
EBITDA
₹1,074.00
Net Income
₹674.00
Total Assets
₹37,387.00
Total Equity
₹31,289.00
Cipla Share Price History - Stock Screener Chart
Screen CIPLA historical share price movements with interactive charts. Analyze price trends and patterns.
Cipla Company Profile - Fundamental Screener
Screen Cipla company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CIPLA shares.
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Y K Hamied
ISIN
INE059A01026
Website
https://www.cipla.com
Cipla Balance Sheet Screener
Screen CIPLA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 | 21,128 |
| Current Assets | 23,249 | 19,392 | 16,805 | 14,711 | 13,210 | 11,706 | 12,427 | 10,814 | 8,736 | 8,841 |
| Fixed Assets | 10,006 | 9,607 | 9,161 | 9,683 | 9,516 | 9,683 | 9,608 | 9,950 | 9,492 | 9,369 |
| Liabilities | ||||||||||
| Total Liabilities | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 | 21,128 |
| Current Liabilities | 614 | 670 | 640 | 1,071 | 1,975 | 3,212 | 4,848 | 4,447 | 4,682 | 1,486 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 31,289 | 26,802 | 23,714 | 21,117 | 18,586 | 16,057 | 15,344 | 14,582 | 12,982 | 11,866 |
| Share Capital | 162 | 162 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 |
| Reserves & Surplus | 31,032 | 26,545 | 23,246 | 20,680 | 18,165 | 15,602 | 14,851 | 14,068 | 12,383 | 11,356 |
Cipla Income Statement Screener - Profit & Revenue Analysis
Screen Cipla income statement and profit fundamentals.
Analyze CIPLA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Cipla share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,169 | 7,716 | 7,096 | 6,887 | 7,183 | 7,152 | 6,785 | 6,332 | 6,690 | 6,766 | 6,406 | 5,801 | 5,845 | 5,882 | 5,421 |
| Expenses | 6,095 | 5,695 | 5,179 | 5,192 | 5,084 | 5,165 | 4,978 | 4,847 | 5,051 | 4,944 | 4,835 | 4,748 | 4,403 | 4,526 | 4,232 |
| EBITDA | 1,074 | 2,022 | 1,916 | 1,695 | 2,099 | 1,986 | 1,807 | 1,484 | 1,639 | 1,821 | 1,571 | 1,053 | 1,442 | 1,356 | 1,190 |
| Operating Profit % | 12.00% | 24.00% | 24.00% | 21.00% | 27.00% | 26.00% | 25.00% | 20.00% | 22.00% | 25.00% | 23.00% | 16.00% | 23.00% | 21.00% | 20.00% |
| Depreciation | 278 | 297 | 253 | 309 | 280 | 272 | 247 | 288 | 233 | 290 | 239 | 346 | 272 | 299 | 254 |
| Interest | 14 | 13 | 14 | 14 | 15 | 15 | 18 | 18 | 30 | 26 | 16 | 34 | 32 | 26 | 18 |
| Profit Before Tax | 893 | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 | 1,611 | 1,259 | 1,474 | 1,594 | 1,375 | 745 | 1,218 | 1,100 | 975 |
| Tax | 219 | 500 | 478 | 290 | 342 | 484 | 436 | 327 | 405 | 439 | 377 | 224 | 410 | 303 | 268 |
| Net Profit | 674 | 1,353 | 1,292 | 1,214 | 1,575 | 1,305 | 1,176 | 932 | 1,068 | 1,155 | 998 | 522 | 808 | 797 | 706 |
| EPS | 8.37 | 16.73 | 16.07 | 15.13 | 19.45 | 16.13 | 14.58 | 11.63 | 13.08 | 14.01 | 12.34 | 6.51 | 9.92 | 9.78 | 8.51 |
Cipla Cash Flow Screener - Liquidity Fundamentals
Screen CIPLA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 | 1,691 | 1,463 | 2,382 | 1,741 |
| Investing Activities | -3,682 | -2,983 | -2,376 | -1,858 | -2,374 | 114 | -1,688 | -834 | -1,304 | -4,533 |
| Financing Activities | -1,293 | -1,200 | -958 | -1,600 | -1,240 | -2,949 | -349 | -386 | -1,326 | 3,104 |
| Net Cash Flow | 30 | -49 | -97 | -132 | 141 | 234 | -345 | 243 | -248 | 312 |
Cipla Shareholding Pattern Screener
See Cipla shareholding pattern with promoter, FII, and DII holdings.
Check Cipla promoter holding and ownership changes for CIPLA on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 29.20% | 29.19% | 29.21% | 29.21% | 33.47% | 30.91% | 30.92% | 29.19% |
| FII Holding | 26.28% | 25.25% | 24.55% | 23.93% | 25.83% | 27.81% | 28.80% | 26.65% |
| DII Holding | 28.15% | 29.26% | 30.25% | 30.72% | 24.42% | 24.95% | 24.16% | 27.71% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 14.13% | 14.10% | 13.82% | 13.84% | 14.20% | 14.24% | 14.16% | 14.29% |
| Other Holding | 2.23% | 2.20% | 2.16% | 2.29% | 2.08% | 2.09% | 1.95% | 2.15% |
| Shareholder Count | 543,420 | 549,655 | 534,587 | 540,521 | 436,154 | 463,569 | 470,234 | 525,114 |
Cipla Share Dividend Screener - Share Yield Analysis
Check Cipla dividend history with payout and yield data.
View Cipla dividend details including ex-dates and amounts for CIPLA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹16.00 | 1.20% |
| 2024-March | ₹13.00 | 0.90% |
| 2023-March | ₹8.50 | 0.57% |
| 2022-March | ₹5.00 | 0.56% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹4.00 | 0.49% |
| 2019-March | ₹3.00 | 0.71% |
| 2018-March | ₹3.00 | 0.57% |
| 2017-March | ₹2.00 | 0.37% |
Cipla Stock Index Membership
See which indices include Cipla stock.
Check CIPLA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Cipla Market Events Screener - Corporate Actions
Get Cipla corporate actions including splits, bonuses, and buybacks.
Check Cipla stock events that may affect CIPLA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -9.40% |
| 2025-10-30 | 2025-10-30 | Quarterly Result Announcement | NA | 3.54% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -1.20% |
| 2025-07-16 | 2025-07-16 | Annual General Meeting | NA | -1.37% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 13.00 /share | 0.08% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 3.00 /share | 0.08% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 6.81% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -7.57% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -9.10% |
| 2024-08-20 | 2024-08-20 | Annual General Meeting | NA | 15.95% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 13.00 /share | 13.79% |
| 2023-07-21 | 2023-07-21 | Dividend | ₹ 8.50 /share | 11.89% |
| 2022-08-26 | 2022-08-26 | Annual General Meeting | NA | 7.37% |
| 2022-08-08 | 2022-08-10 | Dividend | ₹ 5.00 /share | 9.81% |
| 2021-08-09 | 2021-08-11 | Dividend | ₹ 5.00 /share | 1.56% |
Cipla Competitors Screener - Peer Comparison
Screen CIPLA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Cipla Company Announcements - News Screener
Screen CIPLA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-17 | USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA | View |
| 2026-02-16 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2026-02-13 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-01-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-01-23 | Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2026-01-23 | Board Meeting Outcome for Board Meeting Outcome For Meeting Held On 23Rd January 2026 | View |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-01-23 | Financial Results For Quarter And Nine Months Ended 31St December 2025 | View |
| 2026-01-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-14 | Update On Lanreotide Supply Pursuant To US Food And Drug Administration (USFDA) Inspectional Observations In Form 483 On Pharmathen International S.A. | View |
| 2026-01-09 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-01-07 | Reply On Clarification Sought By Exchange | View |
| 2026-01-07 | Intimation Under Regulation 30(11) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Clarification On USFDA Inspectional Observations In Form 483 On Pharmathen International S.A. | View |